ClinicalTrials.gg
RecruitingNCT06072781RAMP 301Updated Nov 2, 2026

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

A Phase 3 interventional study of avutometinib and Defactinib in Low Grade Serous Ovarian Cancer, sponsored by Verastem, Inc.. Recruiting at 105 sites in 16 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Verastem, Inc. · Phase 3, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Nov 2, 20261 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 275 open to participants now, 452 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
204th of 1,499
270 · median 47
Started
2024
with 78 others
Phase 3
103 of 1,780
17 open now
Primary completion
2028-10
later than 338 of 450 live
Registered
1,559th of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 204th largest by planned enrollment of the 1,499 interventional ones that give a count, is one of 79 that started in 2024, is one of 103 in phase 3, reaches primary completion later than 338 of the 450 other live ones, and was the 1,559th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

275 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Read the detailed description

This international, randomized, open-label, Phase 3 study will compare the investigational combination of avutometinib plus defactinib versus Investigator's Choice of Treatments (ICT) in patients with recurrent LGSOC who have progressed on a prior platinum-based therapy. Avutometinib and defactinib are both types of drugs called kinase inhibitors. Kinase inhibitors block cancer cell growth. The study will compare the progression-free survival (PFS) of the combination of avutometinib plus defactinib versus ICT. The study will also evaluate the effect of the combination on safety, overall survival, other efficacy endpoints, and health-related quality of life and disease related symptoms. The study is being conducted by gynecological cancer specialists. Patients who are eligible and agree to participate in this study will be treated with either a combination of avutometinib with defactinib, or with one of four standard of care NCCN and ESMO treatment recommendations for recurrent LGSOC, and then with subsequent follow up appointments. Patients who originally received one of the standards of care treatments who are determined to have progressive disease may be eligible to crossover to receive the investigational combination avutometinib plus defactinib.Avutometinib and defactinib are investigational drugs that have not been approved by the U.S. Food and Drug Administration (FDA)

03

Conditions studied

  • Low Grade Serous Ovarian Cancer

Browse trials for

Keywords

  • Low Grade Serous Ovarian Cancer
  • KRAS
  • KRAS wt
  • KRAS mt
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for inclusion in the study if they meet the following criteria:

  1. proven LGSOC (ovarian, fallopian, peritoneal)
  2. Documented mutational status of KRAS by a validated tumor-tissue based diagnostic test.
  3. Suitable for treatment with at least one of the Investigator's Choice of Treatments:pegylated liposomal doxorubicin, paclitaxel, letrozole, anastrozole.
  4. Progression or recurrence of LGSOC after at least one prior systemic therapy for disease.
  5. according to v1.1.
  6. An Eastern Cooperative Group () performance status ≤ 1.
  7. Adequate organ function.
  8. Adequate recovery from toxicities related to prior treatments.
  9. For patients with , a negative pregnancy test must be confirmed and agreement to use highly effective method of .
  10. Willingness to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from the study if they meet any of the following criteria:

  1. Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy.
  2. Co-existing high-grade serous ovarian cancer or mixed histology.
  3. Prior treatment with avutometinib, defactinib, or other FAK inhibitors.
  4. History of prior with recurrence \<3 years from the time of enrollment.
  5. Major surgery within 4 weeks, minor surgery within 1 week, or palliative radiotherapy within 1 week of the first dose of study intervention.
  6. Symptomatic requiring or other interventions, known , or spinal cord compression.
  7. An active skin disorder that has required systemic therapy within one year of the first dose of study intervention.
  8. History of medically significant rhabdomyolysis.
  9. For subjects with prior MEK or RAF exposure, Grade 4 toxicity is deemed related to the MEK inhibitor.
  10. Symptomatic bowel obstruction within 3 months of the first dose of study intervention
  11. Concurrent ocular disorders.
  12. Concurrent heart disease or severe obstructive pulmonary disease.
  13. Active or past medical history of interstitial lung disease/pneumonitis, including drug-induced or radiation pneumonitis, pulmonary fibrosis, or adult respiratory distress syndrome (ARDS).
  14. Subjects with the inability to swallow oral medications.
  15. History of to any of the active agents or ingredients of study intervention: peanut, soya, polyoxyl castor oil, etcetc.). Prior hypersensitivity to anthracyclines or anthracenediones if the use of pegylated liposomal doxorubicin (PLD) is planned.
  16. Pregnant or breastfeeding.
  17. Active, uncontrolled infection (bacterial, viral, or fungal) requiring systemic therapy.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    avutometinib + defactinib

    Avutometinib 3.2 mg, PO, twice weekly for 21 days on, 7 days off in a 28-day (4 weeks) cycle in combination with defactinib 200 mg, PO, twice daily for 21 days on, 7 days off in a 28-day(4 week) cycle.

    Drug: avutometinib · Drug: Defactinib

  • Active comparator
    Investigator Choice of Treatment (ICT)

    Patients will receive one of the following therapies as determined by the Investigator: * Pegylated liposomal doxorubicin: 40 mg/m2 IV on Day 1 of each 28-day (4 week) cycle. * Paclitaxel: 80 mg/m2 IV on Days 1, 8, and 15 of each 28-day (4 week) cycle. * Anastrozole: 1 mg, PO, once daily of each 28-day (4 week) cycle. * Letrozole: 2.5 mg, PO, once daily of each 28-day (4 week) cycle.

    Drug: Pegylated liposomal doxorubicin · Drug: Paclitaxel · Drug: Letrozole · Drug: Anastrozole

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) per blinded independent central review (BICR)

    Progression-free survival (PFS) according to RECIST version 1.1, per blinded independent central review (BICR)

    Time frame: Up to 24 months

Secondary outcomes

  1. Overall Survival (OS)

    From the time of first dose of study intervention to PD as assessed per RECIST 1.1 or death from any cause

    Time frame: Up to 5 years

  2. Progression Free Survival (PFS) per investigator assessment

    Progression-free survival (PFS) according to RECIST version 1.1, per blinded independent central review (BICR)

    Time frame: 24 months

  3. Objective response rate (ORR)

    From the time of first dose of study intervention to PD as assessed per RECIST 1.1 by Investigator or death from any cause

    Time frame: 12 months

  4. Duration of Response (DOR)

    From the time of first dose of study intervention to PD as assessed per RECIST 1.1 by Investigator or death from any cause

    Time frame: 12 months

  5. Disease Control Rate (DCR)

    CR+PR+Stable disease

    Time frame: 6 months

  6. Frequency and severity adverse events (AEs) and Serious Adverse Events (SAEs)

    Count of AE and SAEs by grade, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grading scale

    Time frame: 25 months

  7. Area under the plasma concentration-time curve (AUC) of avutometinib, defactinib and relative metabolites

    Area under plasma Concentration (AUC) 0 to t

    Time frame: 5 months

  8. Maximum plasma concentration (Cmax) of avutometinib, defactinib and relative metabolites

    maximum plasma concentration

    Time frame: 5 months

  9. To assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module C30 (QLQ-C30).

    The EORTC QLQ-C30 is a validated questionnaire to assess the quality of life of ovarian cancer patients.

    Time frame: 24 months

  10. To assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Ovarian Cancer module OV28 (QLQ-OV28).

    The EORTC QLQ-OV28 is a validated questionnaire to assess the quality of life of ovarian cancer patients.

    Time frame: 24 months

  11. To assess the health-related quality of life and disease based on EuroQol-5 Dimension 5-level (EQ-5D-5L)

    The EuroQol-5 Dimension 5-level (EQ-5D-5L) is a validated questionnaire used to measure a patient's overall health.

    Time frame: 24 months

07

Study locations

103 of 105 sites recruiting

Showing the first 100 of 105 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, Prendergast E, Oaknin A, Ring K, Colombo N, Holloway RW, Rodrigues M, Chon HS, Gourley C, Santin AD, Thaker PH, Gennigens C, Newman G, Salinas E, Youssoufian H, Moore KN, Lustgarten S, O'Malley DM, Van Gorp T, Grisham RN. The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201. Future Oncol. 2025 Dec;21(30):3859-3871. doi: 10.1080/14796694.2025.2595130. Epub 2025 Dec 12. PubMed 41384753 ↗
  • Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, Prendergast E, Oaknin A, Ring K, Colombo N, Holloway RW, Rodrigues M, Chon HS, Gourley C, Santin AD, Thaker PH, Gennigens C, Newman G, Salinas E, Youssoufian H, Moore KN, Lustgarten S, O'Malley DM, Van Gorp T, Grisham RN. Efficacy and Safety of Avutometinib +/- Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol. 2025 Sep;43(25):2782-2792. doi: 10.1200/JCO-25-00112. Epub 2025 Jul 11. PubMed 40644648 ↗
  • Grisham R, Monk BJ, Van Nieuwenhuysen E, Moore KN, Fabbro M, O'Malley DM, Oaknin A, Thaker P, Oza AM, Colombo N, Gershenson D, Aghajanian CA, Choi CH, Lee YC, Mirza MR, Coleman RL, Cobb L, Harter P, Lustgarten S, Youssoufian H, Banerjee S. GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer. Int J Gynecol Cancer. 2025 Nov;35(11):101832. doi: 10.1136/ijgc-2024-005919. Epub 2025 Apr 19. PubMed 39375168 ↗
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Oct 2028, 54 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 54 months is above that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 10, 2023
StartActual
Mar 18, 2024
Primary completionEst.
Oct 15, 2028
CompletionEst.
Feb 9, 2031
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Spedali Civili · Brescia, Italy
Nov 2, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Allegheny Health Network · Pittsburgh, United StatesContact s•••@ahn.org→t•••@ahn.org · •••1116
  • H.U. Ramón y Cajal · Madrid, SpainContact i•••@salud.madrid.org→m•••@salud.madrid.org · •••8263Contact added r•••@salud.madrid.org · •••8263
across 2 updates, Oct 7, 2026 – Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    1 site removed
    Show 1 removed
    • Spedali Civili · Brescia, Italy
    Site contacts Changed at 1 site. See the sites
    Show the site
    • H.U. Ramón y Cajal · Madrid, SpainContact i•••@salud.madrid.org→m•••@salud.madrid.org · •••8263Contact added r•••@salud.madrid.org · •••8263
  2. Oct 7, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Allegheny Health Network · Pittsburgh, United StatesContact s•••@ahn.org→t•••@ahn.org · •••1116
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06072781
Lead sponsor
Verastem, Inc.
Collaborators
GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group, Korean Gynecologic Oncology Group
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Mar 18, 2024
Primary completion
Oct 15, 2028 (estimated)
Completion
Feb 9, 2031 (estimated)
Last update
Nov 2, 2026

Study contacts

Verastem Call Center
Contact
RAMP301TrialSupport@verastem.com
781-292-4204
Rachel Grisham, MD
principal investigator · GOG Foundation
Susana Banerjee, MBBS, MA, PhD
principal investigator · European Network of Gynaecological Oncological Trial Groups (ENGOT)
Yang Liu Verastem Medical Monitor
study director · RAMP301@verastem.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: RO5126766 · Defactinib

Start the discussion